Glaucoma Surgery Devices Market: Investment Opportunities in Emerging Markets

The global glaucoma surgery devices market was valued at approximately USD 1.57 billion in 2022 and is projected to grow at a CAGR of 4.61% from 2025 to 2030. Key drivers of this growth include an aging population, increased adoption of surgical treatments for glaucoma, a rise in government and non-government initiatives focused on glaucoma care, and a heightened prevalence of diabetes.

Lifestyle changes have contributed to the rising incidence of various diseases that lead to visual impairment, such as diabetes and hypertension. Conditions such as cataracts, glaucoma, age-related macular degeneration, and diabetic retinopathy are significant contributors to global visual impairment and blindness. Increased government efforts to raise awareness about visual impairments are expected to further drive market growth.

According to the World Health Organization (WHO), approximately 6.9 million people worldwide suffer from glaucoma. The rising rates of visual impairment also present social and economic challenges. Countries such as China, India, and those in sub-Saharan Africa experience high incidences of eye disorders, including cataracts and glaucoma. The VISION 2020: Right to Sight-INDIA initiative, launched by the WHO in partnership with the Indian government, aims to address these issues through local and international NGO collaboration.

Key Market Trends & Insights

• Market Dominance in North America: The region accounted for the largest market share of 37.26% in 2022 and is expected to maintain this dominance during the forecast period. Contributing factors include an increasing geriatric population, a growing burden of diabetes stemming from lifestyle changes, rising obesity rates, and high treatment costs.

• Product Segmentation: The traditional surgery devices segment dominated the market, capturing over 40% of global revenue in 2022. This preference is attributed to the widespread acceptance of traditional glaucoma surgery, particularly trabeculectomy.

• Surgical Methods: The traditional glaucoma surgery segment held a market share of 35.11% in 2022. While more invasive than newer minimally invasive glaucoma surgeries (MIGS), traditional surgeries remain highly effective for advanced or refractory glaucoma cases.

• End-Use Segmentation: The market is divided into hospitals, ophthalmic clinics, and other settings. Hospitals held the largest market share of 36.68% in 2022 and are expected to exhibit strong growth throughout the forecast period.

Order a free sample PDF of the Glaucoma Surgery Devices Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2022 Market Size: USD 1.57 Billion

• 2030 Projected Market Size: USD 2.27 Billion

• CAGR (2023-2030): 4.61%

• North America: Largest market in 2022

Key Companies & Market Share Insights

The market for glaucoma surgery devices is highly fragmented. Key players are actively pursuing strategic initiatives, such as mergers and acquisitions, to enhance their product portfolios. For instance, in April 2023, Nova Eye Medical Ltd. received FDA 510(k) clearance for its canaloplasty product, iTrack Advance, which is designed to reduce intraocular pressure (IOP) in adult patients with primary open-angle glaucoma. In July 2022, iSTAR Medical partnered with AbbVie to expand its glaucoma treatment offerings, allowing AbbVie to diversify its eye care product range effectively.

Key Players

• Alcon, Inc.

• Glaukos Corporation

• Johnson & Johnson Vision

• AbbVie Inc. (Allergan Plc.)

• ASICO, LLC

• Carl Zeiss Meditec AG

• Katalyst Surgical

• Lumenis Lt.

• Ziemer Ophthalmic Systems AG

• Iridex Corporation.

• Altomed

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The Glaucoma Surgery Devices market is poised for significant growth, driven by advancements in surgical technology and an increasing prevalence of glaucoma worldwide. As new devices and techniques continue to emerge, healthcare providers are better equipped to enhance patient outcomes and optimize treatment processes. The integration of minimally invasive surgery and innovative monitoring solutions are setting new standards in glaucoma management.